Hepatobiliary neuroendocrine carcinoma: a case report by Manxhuka-Kerliu, Suzana et al.
CASE REPORT Open Access
Hepatobiliary neuroendocrine carcinoma:
a case report
Suzana Manxhuka-Kerliu
1*, Gordana Petrusevska
2, Halit Maloku
3, Vjollca Sahatciu-Meka
4, Sadushe Loxha
5,
Naim Loxha
6, Labinot Shahini
7
Abstract
Introduction: Neuroendocrine carcinoma of the gallbladder is a rather uncommon disease. We report a case of a
neuroendocrine tumor that was located in the wall of the gallbladder and that extended into the liver.
Case presentation: A 52-year-old Caucasian woman presented with right-sided abdominal pain, ascites and
jaundice. An MRI scan revealed a tumor mass located in the gallbladder wall and involving the liver. A partial
hepatectomy and cholecystectomy were performed. Histology revealed a neuroendocrine tumor, which showed
scattered Grimelius positive cells and immuno-expressed epithelial and endocrine markers. Our patient is
undergoing chemotherapy treatment.
Conclusion: Gastroenteropancreatic neuroendocrine tumors need a multidisciplinary approach, involving
immunohistochemistry and molecular-genetic techniques.
Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) constitute a heterogeneous group of neoplasms.
Two major GEP-NET subcategories are intestinal endo-
crine tumors or carcinoids and pancreatic neuroendo-
crine tumors (PNETs).
Requests for standardization in the management of
patients with gastroenteropancreatic NETs recently
resulted in the development of several guidelines, includ-
ing those proposed by ENETS. The TNM staging system
and the grading system are based on the current WHO
classifications of endocrine and digestive tumors [1-4].
The classification of GEP-NETs is based on cell mophol-
ogy and the mitotic index, with well-differentiated tumors
displaying monomorphic appearances and rare mitoses
(<2/10 HPF), moderately-differentiated tumors displaying
an intermediate morphology and mitotic rate (2-10/10
HPF) and poorly differentiated tumors consisting of pleo-
morphic cells with a high mitotic index (>10/10 HPF).
These three histology categories of GEP-NETs (well, mod-
erately and poorly differentiated) strongly correlates with
our patient’s survival. Other features of neuroendocrine
tumors (such as secretion of hormones and expression of
somatostatin receptors) also correlate with histological
classification. “Moderately-differentiated” neuroendocrine
tumors should be recognized as a subset of GET-NETs
with a prognosis that is distinct from well- and poorly-dif-
ferentiated tumors [5].
Most endocrine tumors are well differentiated and
slow-growing. A few are poorly differentiated small-cell
endocrine tumors that are rapidly growing and have a
poor prognosis [6].
Even though the growth of GEP-NETs is slow in com-
parison with adenocarcinomas, it is generally recognized
that, with the exception of 90% of insulinomas, almost
all of them have long-term malignant potential. Most
are malignant at the time of diagnosis, with 60% or
more presenting with metastasis to the liver. The most
common cause of the death is hepatic failure and malig-
nant proliferation.
An active approach to treatment may improve our
patient’s quality and length of life [7].
Management strategies include surgery for cure or pal-
liation, and a variety of other cytoreductive techniques
and medical treatment, including chemotherapy and
biotherapy to control symptoms due to hormone release
and tumor growth, with somatostatin analogues (SSAs)
and alpha-interferon. New biological agents and somatos-
tatin-tagged radionuclides are under investigation [8].
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rent upper quadrant pain, while extrahepatic bile duct
carcinoids typically produce the sudden onset of biliary
colic and painless jaundice and ascites [9]. The histo-
pathology of these tumors may reveal: carcinoids (well-
differentiated endocrine tumors); small cell carcinomas
(poorly differentiated endocrine carcinomas); and mixed
endocrine-exocrine carcinomas [10]. Carcinoid tumors
larger than 2 cm often extend into the liver and metas-
tasize. The prognosis of small-cell carcinomas of the
gallbladder is poor [11].
Case presentation
A 52 year-old Caucasian woman presented with right-
sided abdominal pain (upper quadrant pain), ascites and
jaundice. She had been experiencing the abdominal pain
for one year.
An MRI revealed a tumor mass located in the liver,
extrahepatic bile ducts and gallbladder. Tests done at
the time of admission revealed raised levels of serum
amylase (490-600 IU/L), abnormal liver function
(Gamma-glutamyl transpeptidase 372 IU/L; Alkaline
phosphatase 1309 IU/L) and a total bilirubin of 1.90
mg/dl. With a clinical diagnosis of obstructive jaundice,
our patient underwent imaging studies. The primary
clinical diagnosis was liver tumor. A partial hepatectomy
and cholecystectomy were performed.
Part of the liver measured 16 × 13 × 8 cm and the
gallbladder 9.5 × 3.5 cm. The tumor was located in the
wall of the gallbladder infiltrating the liver. The nodular
mass measured 6 cm at its greatest axis, was found in
the wall of the gallbladder involving the liver, and was a
grey-white to yellow color. Thirteen lymph nodes dia-
meters of 0.3 cm to 1 cm were found.
Specimens were fixed in 10% neutral buffered forma-
lin, and paraffin embedded sections were prepared. The
sections were processed for conventional histopathologi-
cal examination as well as for immunohistochemistry
using a standard avidin-biotin-peroxidase complex tech-
nique. Negative and positive controls were included for
each batch of slides tested.
The tumor was composed of round to fusiform cells
with round to ovoid hyperchromatic nuclei, arranged in
sheets, nests, cords, and festoons. There were rosette-
like structures and tubules present, extensive necrosis,
as well as basophilic staining of the vessels. Mitotic fig-
ures were frequent.
Carcinoma cells were Grimelius positive. In addition,
tumor cells immunoexpressed epithelial markers such as
C K ,C K 7 ,C K 1 9+ / - ,a n de n d o c r i n em a r k e r ss u c ha s
NSE (1+), chromogranin A (1+); while C-KIT was nega-
tive, ER negative, PR negative, Alfa fetoprotein negative,
CEA negative, Ki67 positive (low <5%), Vimentin nega-
tive and synaptophysin negative.
The histopathological diagnosis was a GEP-NET
tumor. Our patient is undergoing targeted therapy,
including: Gleevec (Novartis) (Figure 1, Figure 2, Figure
3, Figure 4, Figure 5, Figure 6, Figure 7, Figure 8).
Discussion
Hepatic neuroendocrine carcinoma is extremely rare
and was first described in 1958 [12]. As of 2001, only 53
Figure 1 Gross examination of the liver and gallbladder.
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Page 2 of 7Figure 2 Tumor cells invading the wall of the gallbladder Hematoxylin and eosin 5×.
Figure 3 Paraffin embedded tissue, histological examination (hematoxylin and eosin 5×).
Manxhuka-Kerliu et al. Journal of Medical Case Reports 2010, 4:53
http://www.jmedicalcasereports.com/content/4/1/53
Page 3 of 7Figure 4 Paraffin embedded tissue, histological examination (hematoxylin and eosin 20×).
Figure 5 Paraffin embedded tissue, Immunohistochemical examination, Cg A (10×).
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Page 4 of 7Figure 6 Paraffin embedded tissue, Immunohistochemical examination, NSE (20×).
Figure 7 Immunohistochemical examination, CK (20×).
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Page 5 of 7cases have been reported in English literature [9]. These
tumors were mostly found in middle-age patients and
were more frequently in women.
Neuroendocrine carcinoma of the gallbladder is
uncommon in humans. Only 4% of epithelial tumors of
the gallbladder are neuroendocrine carcinoma, which is
reported to have a poor prognosis [13,14].
Bile duct and gallbladder neuroendocrine carcinomas
arise from pre-existing neuroendocrine cells in the
epithelium. Molecular genetic techniques will probably
aid in a more clear-cut picture of the molecular back-
ground of oncogenesis and the progression of these
tumors [15].
GEP-NET tumors should be treated with a multidisci-
plinary approach, including a partial hepatectomy, pro-
phylactic cholecystectomy, and an excision of the lymph
nodes and the primary tumor [16-19].
Receptor radionuclide therapy is a promising treat-
ment modality for patients with neuroendocrine
tumors and for whom alternative treatments are lim-
ited [20].
Since 2000, patients with somatostatin receptor-posi-
tive metastatic, inoperable GEP-NETs and malignant
pheochromocytomas have been treated with the radiola-
beled somatostatin analogue [
177Lu-DOTA
0,T y r
3]
octreotate (
177Lu-octreotate). Results
177 of Lu-octreotate
treatment in these patients are promising, with a tumor
size reduction in 47% of the treated patients [21].
Conclusion
Gastroenteropancreatic neuroendocrine tumors need a
multidisciplinary approach, involving immunohisto-
chemistry and molecular-genetic techniques.
Consent
Written informed consent was obtained from our
patient for publication of this case report and accompa-
nying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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Figure 8 Immunohistochemical examination, CK 19 (20×).
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